Testing venetoclax and gilteritinib with ASTX727 for FLT3 leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have AML or high-risk MDS with an FLT3 mutation
- Your disease risk level is intermediate-2 or high-risk (for the specific trial group)
- You can take the study pills by mouth (you’re able to swallow)
- Your heart, liver, and kidney labs are within limits, unless the doctor says they’re caused by your leukemia
- You’re not in the trial if you have certain major infections, uncontrolled serious heart failure, or leukemia in the brain/spinal fluid
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This trial combines three drugs to treat certain types of leukemia or a related blood condition. It may be an option for people who cannot have standard intensive chemo, or for those whose disease has come back.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.